Microangiopathic Hemolytic Anemia (TTP, HUS, DIC)
What is Microangiopathic Hemolytic Anemia (TTP, HUS, DIC)?
Microangiopathic hemolytic anemia is a rare condition where red blood cells are physically destroyed as they travel through damaged or narrowed blood vessels. The small blood vessels become injured or blocked, creating a mechanical shredding effect that breaks apart healthy red blood cells. This process creates fragmented red blood cells called schistocytes, which can be seen under a microscope.
This type of anemia occurs in several serious medical conditions. Thrombotic thrombocytopenic purpura, or TTP, happens when blood clots form in small vessels throughout the body. Hemolytic uremic syndrome, or HUS, typically affects the kidneys and often follows certain bacterial infections. Disseminated intravascular coagulation, or DIC, involves widespread clotting and bleeding throughout the body. All three conditions share the common feature of red blood cell destruction in damaged small vessels.
The body tries to compensate for this red blood cell destruction by making new cells rapidly. This response creates red blood cells of different sizes and stages of maturity. Blood tests can detect these size variations and other signs of ongoing red blood cell damage, providing early clues that something is wrong.
Symptoms
- Fatigue and weakness from anemia
- Pale or yellow skin tone
- Easy bruising or purple spots on the skin
- Fever without obvious infection
- Confusion or changes in mental status
- Headaches or vision changes
- Dark or bloody urine
- Reduced urine output or kidney problems
- Abdominal pain or bloody diarrhea, especially with HUS
- Unusual bleeding from gums or nose
Some people may initially experience only mild fatigue before other symptoms develop. Early detection through blood testing can identify changes before serious complications occur.
Concerned about Microangiopathic Hemolytic Anemia (TTP, HUS, DIC)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Microangiopathic hemolytic anemia develops when small blood vessels become damaged or obstructed. TTP occurs when an enzyme that normally breaks down clotting proteins stops working properly, leading to widespread tiny clots. This can be inherited or acquired through autoimmune reactions. HUS most commonly follows infection with certain strains of E. coli bacteria, often from contaminated food. DIC happens as a complication of severe infections, trauma, cancer, or pregnancy complications when the clotting system becomes overactive.
Risk factors vary by the specific condition. Children under 5 years are at higher risk for HUS after bacterial infections. People with autoimmune conditions face increased risk for TTP. Severe illness, major surgery, sepsis, and certain cancers raise the risk for DIC. Pregnant women may develop similar conditions called HELLP syndrome or preeclampsia. Some medications and medical procedures can also trigger these conditions in susceptible individuals.
How it's diagnosed
Diagnosis requires blood tests that look for signs of red blood cell destruction and organ damage. A complete blood count shows low red blood cells and often low platelets. Red Cell Distribution Width, or RDW, becomes elevated because the mechanical destruction creates fragmented cells of varying sizes. The body produces new red blood cells rapidly to compensate, creating even more size variation. A blood smear viewed under a microscope reveals the characteristic fragmented cells called schistocytes.
Additional tests measure kidney function, liver enzymes, and clotting factors to determine the specific cause. Rite Aid offers testing that includes RDW measurement, which can detect the cell size variations that occur with microangiopathic hemolytic anemia. Your doctor may order specialized tests to confirm the diagnosis and identify whether TTP, HUS, DIC, or another condition is responsible. Early detection through routine blood testing allows for faster treatment and better outcomes.
Treatment options
- Immediate hospitalization for severe cases requiring urgent care
- Plasma exchange therapy for TTP to remove harmful antibodies
- Supportive care for kidney function in HUS cases
- Treatment of underlying infection or condition triggering DIC
- Blood transfusions to replace destroyed red blood cells when needed
- Platelet transfusions in specific situations, though avoided in some cases
- Medications to prevent blood clots or support blood pressure
- Dialysis if kidney function becomes severely impaired
- Hydration and electrolyte management
- Close monitoring of blood counts and organ function
Concerned about Microangiopathic Hemolytic Anemia (TTP, HUS, DIC)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
All three conditions cause microangiopathic hemolytic anemia, but they have different triggers and affected organs. TTP involves widespread clotting due to enzyme deficiency and often affects the brain. HUS typically follows bacterial infection and primarily damages the kidneys. DIC occurs as a complication of severe illness and causes both clotting and bleeding throughout the body.
These conditions typically develop rapidly over days to weeks. Symptoms may start suddenly with fatigue, fever, or confusion. Some people notice bruising or changes in urine color first. Early symptoms can progress quickly to serious complications, making prompt medical attention essential.
Yes, blood tests can show early signs before severe symptoms develop. Red Cell Distribution Width becomes elevated as fragmented cells of varying sizes appear in the bloodstream. A complete blood count reveals dropping red blood cell and platelet levels. These changes may be detectable before serious organ damage occurs.
Elevated RDW means your red blood cells vary significantly in size. In microangiopathic hemolytic anemia, mechanical destruction creates fragmented cells while your body rapidly produces new cells to compensate. This creates a mix of different cell sizes and ages. Higher RDW values reflect more severe ongoing destruction and compensatory production.
The outcome depends on the specific condition and how quickly treatment starts. TTP can often be controlled with plasma exchange therapy, though some people need ongoing treatment. HUS may resolve with supportive care, especially in children, but can cause permanent kidney damage. DIC requires treating the underlying trigger and can resolve if the primary condition improves.
Young children face higher risk for HUS after E. coli infections from contaminated food. People with autoimmune conditions are more prone to TTP. Pregnant women, people with severe infections, cancer patients, and trauma victims have increased risk for DIC. Anyone with a family history of TTP should be aware of their potential genetic risk.
Untreated microangiopathic hemolytic anemia can cause kidney failure requiring dialysis, stroke from brain vessel damage, heart attack, or severe bleeding. Organ damage may become permanent if treatment is delayed. The mortality rate was historically very high for TTP before effective treatments became available. Early recognition and treatment significantly improve survival and reduce long-term complications.
People with known risk factors should work with their doctor to establish a monitoring schedule. Those with autoimmune conditions or family history of TTP may benefit from periodic blood testing. Regular screening can detect early changes in blood cell counts or RDW levels. Twice-yearly comprehensive testing can help catch problems before symptoms develop.
While you cannot prevent inherited forms, you can reduce some risks. Practice safe food handling to avoid E. coli infections that cause HUS. Manage chronic conditions carefully to reduce DIC risk. Stay current with vaccinations and treat infections promptly. Regular blood testing helps detect changes early when treatment is most effective.